Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ ABIONYX Pharma Is Launching a Capital Increase With Cancellation of Preferential Subscription Rights in... (Business Wire) +++ ABIONYX Aktie -4,27%

CHAMPIONS ONCOLOGY Aktie

 >Aktienkurs 
5.7 EUR    -14.9%    (Tradegate)
Ask: 5.8 EUR / 256 Stück
Bid: 5.5 EUR / 274 Stück
Tagesumsatz: 1724 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>Performance
1 Woche: +17,1%
1 Monat: +5,1%
3 Monate: -8,9%
6 Monate: -7,5%
1 Jahr: -3,1%
laufendes Jahr: -22,9%
>CHAMPIONS ONCOLOGY Aktie
Name:  CHAMPIONS ONCOLOGY DL-,01
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US15870P3073 / A14X6S
Symbol/ Ticker:  2I3 (Frankfurt) / CSBR (NASDAQ)
Kürzel:  FRA:2I3, ETR:2I3, 2I3:GR, NASDAQ:CSBR
Index:  -
Webseite:  https://www.championsonco..
Profil:  Champions Oncology, Inc. operates as a biotechnolo..
>Volltext..
Marktkapitalisierung:  73.99 Mio. EUR
Unternehmenswert:  70.17 Mio. EUR
Umsatz:  48.45 Mio. EUR
EBITDA:  3.88 Mio. EUR
Nettogewinn:  2.51 Mio. EUR
Gewinn je Aktie:  0.18 EUR
Schulden:  5.05 Mio. EUR
Liquide Mittel:  8.79 Mio. EUR
Operativer Cashflow:  6.54 Mio. EUR
Bargeldquote:  0.45
Umsatzwachstum:  4.43%
Gewinnwachstum:  -
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  CHAMPIONS ONCOLOGY
Letzte Datenerhebung:  16.12.25
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 13.79 Mio. St.
Frei handelbar: 43.32%
Rückkaufquote: -0.4%
Mitarbeiter: 213
Umsatz/Mitarb.: 0.23 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 97.44%
Bewertung:
KGV: 30.57
KGV lG: 41.86
KUV: 1.48
KBV: 24.01
PEG-Ratio: -
EV/EBITDA: 18.07
Rentabilität:
Bruttomarge: 45.74%
Gewinnmarge: 5.19%
Operative Marge: 5.29%
Managementeffizenz:
Gesamtkaprendite: 10.64%
Eigenkaprendite: 185.89%
>Peer Group

Es sind 599 Aktien bekannt.
 
16.12.25 - 00:18
 Champions Oncology signals expanding radiolabeling and data platform as margin improves to 52% (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
15.12.25 - 23:30
 Earnings call transcript: Champions Oncology meldet starkes Umsatzwachstum für Q2 2025 – Aktie steigt um 16 %/n (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
15.12.25 - 22:09
 Champions Oncology, Inc.: Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million (Accesswire)
 
We remain on track to deliver year-over-year revenue growth and to generate positive adjusted EBITDA for the fiscal year HACKENSACK, NJ / ACCESS Newswire / December 15, 2025 / Champions Oncology, I......
15.12.25 - 22:06
 Champions Oncology Non-GAAP EPS of $0.06, revenue of $15M beats by $0.96M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
08.12.25 - 22:06
 Champions Oncology, Inc.: Champions Oncology to Announce Second Quarter Financial Results on Monday, December 15, 2025 (Accesswire)
 
HACKENSACK, NJ / ACCESS Newswire / December 8, 2025 / Champions Oncology, Inc. (CSBR), a leading translational oncology research organization, will report its financial and operational results for ......
16.09.25 - 00:27
 Champions Oncology targets sequential revenue growth and margin expansion as radiopharma and data platforms advance (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
15.09.25 - 23:06
 Champions Oncology, Inc.: CORRECTION: Champions Oncology Reports Quarterly Revenue of $14.0 Million (Accesswire)
 
This release contains a headline correction from the previous publication.Positive start to FY 2026 with steady revenue, data growth and new leadership HACKENSACK, NJ / ACCESS Newswire / September ......
15.09.25 - 22:06
 Champions Oncology, Inc.: Champions Oncology Reports Record Quarterly Revenue of $14.0 Million (Accesswire)
 
Positive start to FY 2026 with steady revenue, data growth and new leadership HACKENSACK, NJ / ACCESS Newswire / September 15, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational......
15.09.25 - 22:00
 Champions Oncology Non-GAAP EPS of $0.02 beats by $0.03, revenue of $14M beats by $0.49M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
10.09.25 - 22:42
 Champions Oncology, Inc.: Champions Oncology to Announce First Quarter Financial Results on Monday, September 15, 2025 (Accesswire)
 
HACKENSACK, NJ / ACCESS Newswire / September 10, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solution......
23.07.25 - 22:06
 Champions Oncology, Inc.: Champions Oncology Reports Record Annual Revenue of $57 Million (Accesswire)
 
Total annual revenue growth of 14% HACKENSACK, NJ / ACCESS Newswire / July 23, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced......
21.07.25 - 14:42
 Champions Oncology, Inc.: Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Wednesday, July 23, 2025 (Accesswire)
 
HACKENSACK, NJ / ACCESS Newswire / July 21, 2025 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will repo......
18.07.25 - 14:42
 Champions Oncology, Inc.: Champions Oncology Announces Appointment of New CEO (Accesswire)
 
HACKENSACK, NJ / ACCESS Newswire / July 18, 2025 / Champions Oncology (NASDAQ:CSBR), a leading provider of oncology-focused CRO services specializing in preclinical and clinical specialty testing, ......
08.07.25 - 14:42
 Champions Oncology lanciert Plattform für radiopharmazeutische Dienstleistungen, erweitert seine Isotopen-Lizenz und screent über 30 PDX-Modelle (IRW Press)
 
Erweitertes Angebot ermöglicht integrierte radiopharmazeutische Studien unter Einsatz von klinisch relevanten Isotopen und hochgradig charakterisierten PDX-Tumormodellen HACKENSACK, NJ / ACCESS......
08.07.25 - 14:42
 Champions Oncology, Inc.: Champions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License, and Screens More Than 30 PDX Models (Accesswire)
 
Expanded offering delivers integrated radiopharmaceutical studies using clinically relevant isotopes and highly characterized PDX tumor models HACKENSACK, NJ / ACCESS Newswire / July 8, 2025 / Cham......
28.04.25 - 16:18
 Champions Oncology, Inc.: Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House (Accesswire)
 
HACKENSACK, NJ / ACCESS Newswire / April 28, 2025 / Champions Oncology (NASDAQ:CSBR), a leader in translational oncology research, has been granted a license to use radioactive materials in preclin......
24.04.25 - 14:18
 Champions Oncology, Inc.: Champions Oncology′s Data Platform Gains Momentum through a Strategic Collaboration with Turbine (Accesswire)
 
HACKENSACK, NJ / ACCESS Newswire / April 24, 2025 / Champions Oncology (NASDAQ:CSBR), a global leader in oncology R&D solutions, has announced a strategic collaboration with Turbine, the creators o......
11.03.25 - 21:06
 Champions Oncology, Inc.: Champions Oncology Reports Record Quarterly Revenue of $17.0 Million Record Net Income of $4.5 Million (Accesswire)
 
HACKENSACK, NJ / ACCESS Newswire / March 11, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, t......
06.03.25 - 22:09
 Champions Oncology, Inc.: Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 11, 2025 (Accesswire)
 
HACKENSACK, NJ / ACCESS Newswire / March 6, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, wi......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Abwechslung verschafft Appetit. - Sprichwort Großbritannien
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!